Understand the Role of Radicava in Amyotrophic Lateral Sclerosis (ALS)

June 2019

Radicava (ra-dih-CAH-vah, edaravone) is the first treatment approved for amyotrophic lateral sclerosis (ALS) in almost 20 years.

Until now, we've only had riluzole (Rilutek) for this progressive, degenerative nerve disease...also known as Lou Gehrig's disease.

Radicava is a free-radical scavenger...and oxidative stress is one way that cell damage and cell death may occur in ALS.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Opioids Start a Dialogue About Tapering Chronic Opioids
Gastroenterology Don't Think of Meds as a Significant Source of Gluten
Diabetes Weigh Pros and Cons of SGLT2 Inhibitors for Kidney Protection
Glaucoma Keep an Eye Out for Vyzulta to Treat Open-Angle Glaucoma
HIV & AIDS Expect to See Fewer Antibiotics for MAC Prophylaxis in Patients With HIV
Diabetes Watch for Med Changes When Diabetes Patients Have Surgery
Infectious Diseases Don't Advise Screening for UTIs in Most Patients Without Symptoms
Warts Tell Patients to Be Persistent When Treating Warts
Neurology & Pain Understand the Role of Radicava in Amyotrophic Lateral Sclerosis (ALS)
Insomnia Explain Risk of Strange Sleep Behaviours With "Z-Drugs"